Correction to: Determinants of activity and efficacy of anti-PD1/PD-L1 therapy in patients with advanced solid tumors recruited in a clinical trials unit: a longitudinal prospective biomarker-based study
Cancer Immunol Immunother. 2023 Jun;72(6):1725-1726.
doi: 10.1007/s00262-023-03396-5.
1 Medical Oncology Department, Hospital Clinic of Barcelona, Barcelona, Spain.
2 Medical Oncology Department (UGCI), Virgen de La Victoria and Regional University Hospital / IBIMA, Málaga, Spain.
3 Medical Oncology Department, Hospital General of Granollers, Barcelona, Spain.
4 Immunology Department, Hospital Clinic of Barcelona, Barcelona, Spain.
5 Translational Genomics and Targeted Therapies in Solid Tumours Group, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain.
6 Medical Oncology Department, University Hospital, 12 de Octubre, Madrid, Spain.
7 Pathology Department, Diagnostic Biomedical Center, Hospital Clinic of Barcelona, Barcelona, Spain.
8 Departament de Medicina, Facultat de Medicina i Ciències de la Salut, Universitat de Barcelona, c. Casanova, 143, 08036, Barcelona, Spain.
9 Medical Oncology Department, Hospital Clinic of Barcelona, Barcelona, Spain. [email protected].
10 Translational Genomics and Targeted Therapies in Solid Tumours Group, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain. [email protected].
11 Departament de Medicina, Facultat de Medicina i Ciències de la Salut, Universitat de Barcelona, c. Casanova, 143, 08036, Barcelona, Spain. [email protected].
12 Medical Oncology Department, Hospital Clinic of Barcelona, Barcelona, Spain. [email protected].
13 Translational Genomics and Targeted Therapies in Solid Tumours Group, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain. [email protected].
14 Departament de Medicina, Facultat de Medicina i Ciències de la Salut, Universitat de Barcelona, c. Casanova, 143, 08036, Barcelona, Spain. [email protected].